DK0440777T3 - Neurotrofisk faktor stammende fra hjernen - Google Patents

Neurotrofisk faktor stammende fra hjernen

Info

Publication number
DK0440777T3
DK0440777T3 DK90913361.3T DK90913361T DK0440777T3 DK 0440777 T3 DK0440777 T3 DK 0440777T3 DK 90913361 T DK90913361 T DK 90913361T DK 0440777 T3 DK0440777 T3 DK 0440777T3
Authority
DK
Denmark
Prior art keywords
bdnf
nucleic acid
ngf
acid sequences
relates
Prior art date
Application number
DK90913361.3T
Other languages
English (en)
Inventor
Carolyn Hyman
Ralph Alderson
George Yancopoulos
Yves-Alain Barde
Hans F E Thoenen
Andreas Hohn
Friedrich Lottspeich
Ronald M Lindsay
Magdalena Hofer
Joachim Leibrock
Bastian Hengerer
Dan Lindholm
Francisco Zafra
David Edgar
Original Assignee
Max Planck Gesellschaft
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/400,591 external-priority patent/US5180820A/en
Application filed by Max Planck Gesellschaft, Regeneron Pharma filed Critical Max Planck Gesellschaft
Application granted granted Critical
Publication of DK0440777T3 publication Critical patent/DK0440777T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F02—COMBUSTION ENGINES; HOT-GAS OR COMBUSTION-PRODUCT ENGINE PLANTS
    • F02B—INTERNAL-COMBUSTION PISTON ENGINES; COMBUSTION ENGINES IN GENERAL
    • F02B75/00—Other engines
    • F02B75/02—Engines characterised by their cycles, e.g. six-stroke
    • F02B2075/022—Engines characterised by their cycles, e.g. six-stroke having less than six strokes per cycle
    • F02B2075/027—Engines characterised by their cycles, e.g. six-stroke having less than six strokes per cycle four
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
DK90913361.3T 1989-08-30 1990-08-29 Neurotrofisk faktor stammende fra hjernen DK0440777T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/400,591 US5180820A (en) 1989-08-30 1989-08-30 Brain-derived neurotrophic factor
US07/570,657 US5229500A (en) 1989-08-30 1990-08-20 Brain derived neurotrophic factor

Publications (1)

Publication Number Publication Date
DK0440777T3 true DK0440777T3 (da) 1997-04-21

Family

ID=27017110

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90913361.3T DK0440777T3 (da) 1989-08-30 1990-08-29 Neurotrofisk faktor stammende fra hjernen

Country Status (20)

Country Link
US (2) US5229500A (da)
EP (1) EP0440777B1 (da)
KR (1) KR100188189B1 (da)
CN (1) CN1124343C (da)
AT (1) ATE148921T1 (da)
AU (1) AU647412B2 (da)
CA (1) CA2040412C (da)
DE (1) DE69029934T2 (da)
DK (1) DK0440777T3 (da)
ES (1) ES2098271T3 (da)
FI (1) FI105342B (da)
HK (1) HK1006578A1 (da)
IE (1) IE903128A1 (da)
IL (1) IL95512A0 (da)
LV (1) LV10725B (da)
NO (1) NO303584B1 (da)
PT (1) PT95152B (da)
SG (1) SG46954A1 (da)
SK (1) SK279668B6 (da)
WO (1) WO1991003568A1 (da)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5844072A (en) 1992-05-26 1998-12-01 University Of California Antibiotic cryptdin peptides and methods of their use
US6780837B1 (en) * 1989-08-30 2004-08-24 The Regents Of The University Of California Prevention of retinal injury and degeneration by specific factors
US5229500A (en) * 1989-08-30 1993-07-20 Regeneron Pharmaceuticals, Inc. Brain derived neurotrophic factor
US5180820A (en) * 1989-08-30 1993-01-19 Barde Yves Alain Brain-derived neurotrophic factor
IL95511A (en) * 1989-08-30 2000-10-31 Max Planck Gesellschaft Neurotrophin-3 a novel neurotrophic factor related to nerve growth and brain derived neurotrophic factor
US5235043A (en) * 1990-04-06 1993-08-10 Synergen, Inc. Production of biologically active, recombinant members of the ngf/bdnf family of neurotrophic proteins
US5986070A (en) * 1990-04-06 1999-11-16 Amgen Inc. Production of biologically active NGF proteins
AU2010592A (en) * 1991-05-20 1992-12-30 Case Western Reserve University Neurotrophic factor, preparation and uses thereof
US5389529A (en) * 1991-06-12 1995-02-14 Regeneron Pharmaceuticals, Inc. Modified lamβ signal sequence and processes for producing recombinant neurotrophins
EP0593663A4 (en) * 1991-07-03 1996-10-30 Regeneron Pharma Method and assay system for neurotrophin activity
ZA923639B (en) * 1991-07-10 1993-02-24 Regeneron Pharma Methods of treatment of motor neuron diseases using members of the bdnf/nt-3/ngf family of molecules
DE4237047A1 (en) * 1991-11-04 1993-05-06 I N R O Handels-Gmbh, 8750 Aschaffenburg, De Drug contg. polypeptide homologous to nerve growth factor and slow virus sequence - for treating amyotrophic lateral sclerosis, spinal muscle atrophy or Parkinson's disease
ATE193207T1 (de) * 1992-02-14 2000-06-15 Regeneron Pharma Vorbeugung von verletzungen und degenerationen von photorezeptoren durch neurotrophische faktoren
US6451763B1 (en) 1992-06-04 2002-09-17 The United States Of America As Represented By The Department Of Health And Human Services Retinal pigmented epithelium derived neurotrophic factor and methods of use
CA2137377C (en) * 1992-06-04 2011-03-08 Lincoln V. Johnson Retinal pigmented epithelium derived neurotrophic factor
ATE206056T1 (de) * 1992-06-08 2001-10-15 Takeda Chemical Industries Ltd Therapeutisches agens für neutropenie
WO1994003199A1 (en) * 1992-08-04 1994-02-17 Regeneron Pharmaceuticals, Inc. Method of enhancing differentiation and survival of neuronal precursor cells
IL134656A (en) * 1992-09-03 2006-12-10 Univ California Antibodies that bind the polypeptide nogin and hybridoma capable of producing these antibodies
ES2149823T3 (es) * 1992-09-03 2000-11-16 Univ California Factor y composiciones que afectan al tejido dorsal.
US20040224409A1 (en) * 1992-09-25 2004-11-11 Laurent Pradier Recombinant adenoviruses coding for brain-derived neurotrophic factor (BDNF)
IL109280A0 (en) * 1993-04-15 1994-07-31 Regeneron Pharma Neurotrophins for treatment of depression
ATE163006T1 (de) * 1993-06-01 1998-02-15 Ono Pharmaceutical Co Pentansäurederivate
WO1995006656A1 (en) * 1993-09-03 1995-03-09 The Regents Of The University Of California Neural tissue affecting factor and compositions
US6652850B1 (en) 1993-09-13 2003-11-25 Aventis Pharmaceuticals Inc. Adeno-associated viral liposomes and their use in transfecting dendritic cells to stimulate specific immunity
WO1995012686A1 (en) * 1993-11-03 1995-05-11 Cephalon, Inc. Method for screening for compounds which change the tyrosine hydroxylase content of intact cells in culture
US5556837A (en) * 1994-08-01 1996-09-17 Regeneron Pharmaceuticals Inc. Methods for treating addictive disorders
ATE232089T1 (de) * 1994-11-10 2003-02-15 Univ Kentucky Res Found Implantierbare wiederauffüllbare vorrichtung mit gesteuerter freisetzung zur verabreichung von arzneistoffen unmittelbar an einen inneren teil des körpers
US5770577A (en) * 1994-11-14 1998-06-23 Amgen Inc. BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
US5679783A (en) * 1994-11-22 1997-10-21 The Regents Of The University Of California DNA encoding a tissue differentiation affecting factor
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
JP3093974B2 (ja) * 1995-06-27 2000-10-03 住友ベークライト株式会社 神経細胞用培養液、その製造方法及びこれを用いる神経細胞の培養方法
US5830857A (en) * 1995-07-14 1998-11-03 Amgen Inc. Method of treating epilepsy
US6743628B1 (en) * 1995-08-28 2004-06-01 Washington University Method of cell culture using neurturin
US6184200B1 (en) 1995-09-28 2001-02-06 Amgen Inc. Truncated glial cell line-derived neurotrophic factor
US5731284A (en) * 1995-09-28 1998-03-24 Amgen Inc. Method for treating Alzheimer's disease using glial line-derived neurotrophic factor (GDNF) protein product
US5859311A (en) * 1995-11-27 1999-01-12 University Of Kentucky Research Foundation Transgenic mice which overexpress neurotrophin-3 (NT-3) and methods of use
US6225282B1 (en) * 1996-01-05 2001-05-01 Genentech, Inc. Treatment of hearing impairments
US5958875A (en) * 1996-03-29 1999-09-28 The Regents Of The University Of California Synthetic peptides derivatives with nerve growth factor-like neurotrophic activity
GB9608335D0 (en) * 1996-04-23 1996-06-26 Univ Kingston Method of enhancing ngf-mediated neurite growth with low molecular weight analoues of p.75 ngfr 367-379
WO1998003546A1 (en) * 1996-07-19 1998-01-29 Amgen Inc. Analogs of cationic proteins
PL191400B1 (pl) * 1996-11-15 2006-05-31 Genentech Inc Sposób izolowania neurotrofiny z mieszaniny białek i kompozycja neurotrofiny
KR20000070357A (ko) 1997-01-23 2000-11-25 다께우찌 마사야쓰 당뇨병 치료제
WO1999024572A1 (en) * 1997-11-11 1999-05-20 Universiteit Utrecht Genes with restricted expression in mesencephalic dopaminergic neurons
US6331523B1 (en) 1998-03-12 2001-12-18 Genentech, Inc. Method of enhancing the survival of retinal neurons and treating ocular diseases using FGF-5
EP1126869B1 (en) * 1998-10-28 2008-09-03 Cornell Research Foundation, Inc. Methods for regulating angiogenesis and vascular integrity using the trk receptor ligands bdnf, nt-3 and nt-4
US20040120891A1 (en) * 1998-12-21 2004-06-24 Craig Hill Compounds for intracellular delivery of therapeutic moieties to nerve cells
AU780408B2 (en) * 1999-06-08 2005-03-17 Calibre Biotechnology Pty Limited Small cyclic mimics of brain-derived neurotrophic factor (BDNF)
AUPQ084899A0 (en) * 1999-06-08 1999-07-01 University Of Melbourne, The Neurotrophin agonists
CA2383076A1 (en) * 1999-09-16 2001-03-22 Neurotrophic Bioscience, Inc. Dopaminergic neuronal survival-promoting factors and uses thereof
WO2001066133A1 (fr) * 2000-03-06 2001-09-13 Sumitomo Pharmaceuticals Company, Limited Agents d'amelioration de la resistance a la leptine
US6784335B2 (en) 2000-06-29 2004-08-31 Deltagen, Inc. Transgenic mice containing BMP gene disruptions
WO2002007757A2 (en) * 2000-07-21 2002-01-31 Lue Tom F Prevention and treatment of sexual arousal disorders
US7223406B2 (en) * 2000-07-21 2007-05-29 The Regents Of The University Of California Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
US6902881B2 (en) 2000-10-13 2005-06-07 President And Fellows Of Harvard College Compounds and methods for regulating cell differentiation
US20030050273A1 (en) * 2001-08-29 2003-03-13 Keiya Ozawa Compositions and methods for treating neurodegenerative diseases
US7615676B2 (en) 2001-11-30 2009-11-10 U.S. Department Of Veterans Affairs Transgenic screen and method for screening modulators of brain-derived neurotrophic factor (BDNF) production
US7491810B2 (en) 2001-11-30 2009-02-17 U.S. Department Of Veterans Affairs Transgenic screen and method for screening modulators of brain-derived neurotrophic factor (BDNF) production
US20030124095A1 (en) * 2001-12-31 2003-07-03 Regents Of The University Of California Methods for therapeutic use of brain derived neurotrophic factor in the entorhinal cortex
US20030219696A1 (en) * 2002-05-23 2003-11-27 Moreland Gerald W. Method and apparatus for preventing backflow in dental saliva evacuators
WO2004041778A2 (en) * 2002-11-01 2004-05-21 University Of Medicine And Dentistry Of New Jersey A method for increasing synaptic growth or plasticity
US20050265983A1 (en) * 2002-11-17 2005-12-01 Eldad Melamed Methods, nucleic acid constructs and cells for treating neurodegenerative disorders
US7388079B2 (en) * 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
US20050048041A1 (en) * 2003-01-13 2005-03-03 Rao Mahendra S. Persistent expression of candidate molecule in proliferating stem and progenitor cells for delivery of therapeutic products
CN1871024B (zh) * 2003-09-09 2012-03-28 智再如股份有限公司 牙周病和牙髓疾病的治疗剂以及治疗方法
PT2206728T (pt) 2004-04-07 2018-04-17 Rinat Neuroscience Corp Métodos de tratamento da dor associada ao cancro ósseo através da administração de um anticorpo antagonista do fator de crescimento nervoso
ES2446250T3 (es) * 2005-05-02 2014-03-06 University Of Southern California Marcadores de metilación del ADN asociados con el fenotipo metilador de islas CpG (CIMP) en el cáncer colorrectal humano
ES2524996T3 (es) 2005-06-16 2014-12-16 Ramot At Tel Aviv University Ltd. Células aisladas y poblaciones que comprenden a las mismas para el tratamiento de enfermedades del SNC
US8741260B2 (en) * 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
US8142781B2 (en) * 2005-10-07 2012-03-27 Armagen Technologies, Inc. Fusion proteins for blood-brain barrier delivery
US8124095B2 (en) * 2005-10-07 2012-02-28 Armagen Technologies, Inc. Fusion proteins for delivery of erythropoietin to the CNS
WO2007066338A1 (en) * 2005-12-08 2007-06-14 Ramot At Tel Aviv University Ltd. Isolated oligodendrocyte-like cells and populations comprising same for the treatment of cns diseases
US20100035877A1 (en) * 2006-06-26 2010-02-11 Katz David M Methods and compositions for treating pathologies associated with bdnf signaling
US8759297B2 (en) 2006-08-18 2014-06-24 Armagen Technologies, Inc. Genetically encoded multifunctional compositions bidirectionally transported between peripheral blood and the cns
US20090011040A1 (en) * 2007-05-02 2009-01-08 Naash Muna I Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases
WO2009018122A2 (en) 2007-07-27 2009-02-05 Armagen Technologies, Inc. Methods and compositions for increasing alpha-iduronidase activity in the cns
US20090196854A1 (en) * 2008-02-04 2009-08-06 Kytos Biosystems S.A. Methods and compositions for use of crl 5803 cells for expression of biotherapeutics and encapsulated cell-based delivery
EP2620493B1 (en) 2008-05-28 2019-03-27 Ramot at Tel Aviv University Ltd. Mesenchymal stem cells for the treatment of CNS diseases
WO2010108048A2 (en) 2009-03-18 2010-09-23 Armagen Technologies, Inc. Compositions and methods for blood-brain barrier delivery of igg-decoy receptor fusion proteins
ES2725200T3 (es) * 2009-10-09 2019-09-20 Armagen Inc Métodos y composiciones para aumentar la actividad de iduronato 2-sulfatasa en el SNC
EP2594295A1 (en) 2011-11-16 2013-05-22 Servicio Andaluz De Salud Nerve implants based on a compacted biomaterial containing cells
US8486399B2 (en) 2011-12-02 2013-07-16 Armagen Technologies, Inc. Methods and compositions for increasing arylsulfatase A activity in the CNS
CN105017406B (zh) * 2014-04-21 2020-10-09 上海市第一人民医院 一类新的具有神经保护功能的多肽
US10538589B2 (en) 2015-01-14 2020-01-21 Armagen Inc. Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
GB2547179A (en) 2015-10-26 2017-08-16 Quethera Ltd Genetic construct
AU2017385274B2 (en) 2016-12-26 2024-02-22 Jcr Pharmaceuticals Co., Ltd. Fusion protein including BDNF
KR20200095455A (ko) 2017-08-28 2020-08-10 상하이 일레 바이오테크놀로지 씨오., 엘티디. 폴리펩티드 및 폴리펩티드에 결합되는 항체
MX2021000644A (es) 2018-07-18 2021-08-19 Manzanita Pharmaceuticals Inc Conjugados para suministrar un agente contra el cancer a las celulas nerviosas, metodos de uso y metodos para la elaboracion de los mismos.
CN116543838B (zh) * 2023-07-05 2023-09-05 苏州凌点生物技术有限公司 一种生物基因选择表达概率的数据分析方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3123963C2 (de) * 1981-06-19 1985-05-15 Berchem & Schaberg Gmbh, 4650 Gelsenkirchen Gesteinsschneidkopf für einen Schneidkopf-Saugbagger
DE3213963A1 (de) * 1982-04-15 1983-10-27 Max Planck Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Neurotropher faktor
US4935370A (en) * 1983-12-23 1990-06-19 Pfizer Inc. Expression plasmids for improved production of heterologous protein in bacteria
CA1310602C (en) * 1986-06-03 1992-11-24 Hajime Horii Yeast promoter and process for preparing heterologous protein
IL95511A (en) * 1989-08-30 2000-10-31 Max Planck Gesellschaft Neurotrophin-3 a novel neurotrophic factor related to nerve growth and brain derived neurotrophic factor
US5229500A (en) * 1989-08-30 1993-07-20 Regeneron Pharmaceuticals, Inc. Brain derived neurotrophic factor
US5235043A (en) * 1990-04-06 1993-08-10 Synergen, Inc. Production of biologically active, recombinant members of the ngf/bdnf family of neurotrophic proteins

Also Published As

Publication number Publication date
WO1991003568A1 (en) 1991-03-21
FI105342B (fi) 2000-07-31
AU6337390A (en) 1991-04-08
EP0440777A1 (en) 1991-08-14
EP0440777B1 (en) 1997-02-12
NO911689L (no) 1991-06-25
US5229500A (en) 1993-07-20
NO911689D0 (no) 1991-04-29
DE69029934T2 (de) 1997-07-24
KR920701432A (ko) 1992-08-11
ATE148921T1 (de) 1997-02-15
SG46954A1 (en) 1998-03-20
CN1052142A (zh) 1991-06-12
CA2040412C (en) 2003-03-18
AU647412B2 (en) 1994-03-24
FI912104A0 (fi) 1991-04-30
SK422990A3 (en) 1999-02-11
LV10725A (lv) 1995-06-20
CN1124343C (zh) 2003-10-15
NO303584B1 (no) 1998-08-03
KR100188189B1 (en) 1999-06-01
PT95152A (pt) 1991-05-22
SK279668B6 (sk) 1999-02-11
IE903128A1 (en) 1991-03-13
EP0440777A4 (en) 1992-05-13
DE69029934D1 (de) 1997-03-27
IL95512A0 (en) 1991-06-30
LV10725B (en) 1995-12-20
US5438121A (en) 1995-08-01
HK1006578A1 (en) 1999-03-05
ES2098271T3 (es) 1997-05-01
CA2040412A1 (en) 1991-03-01
PT95152B (pt) 1998-06-30

Similar Documents

Publication Publication Date Title
DK0440777T3 (da) Neurotrofisk faktor stammende fra hjernen
GR900100653A (el) Νευροτροφικός παράγοντας που προέρχεται από τον εγκέφαλο.
Maruyama et al. A novel brain-specific mRNA encoding nuclear protein (necdin) expressed in neurally differentiated embryonal carcinoma cells
HUP0300067A2 (en) Novel method for down-regulation of amyloid
EP0448707A4 (en) Ciliary neurotrophic factor
ATE94547T1 (de) Pharmazeutische zubereitung enthaltend eine tetrahydropyrrolverbindung als aktiven bestandteil und verfahren zur herstellung dieser tetrapyrrolverbindung.
DK0414275T3 (da) Fremgangsmåde til fremtilling af cycliske aminosyrederivater samt mellemprodukter
ATE106454T1 (de) Kennzeichnung und nachweis von mit autoimmunkrankheiten assoziierten sequenzen.
DE3583564D1 (de) Dna-sequenzen des ebv-genoms, rekombinante dna-molekuele, verfahren zur herstellung von ebv-verwandten antigenen sowie diagnostische zusammensetzungen und pharmazeutische zusammensetzungen, die die genannten antigene enthalten.
ATE106748T1 (de) Vakzine zum schutz vor hiv-virusinfektionen, verfahren zu ihrer herstellung und ihre verwendung als diagnostikum und immuntherapeutikum.
EP0192988A3 (en) Process for solubilization, purification and characterization of protein from insoluble protein aggregates or complexes and compositions of matter therefrom
DK0562508T3 (da) Nyt knogle-relateret protein OSF-2, fremgangsmåde til dets fremstilling samt farmaceutisk præparat med indhold deraf
Doolittle The amino-terminal amino acid sequences of rabbit immunoglobulin light chains.
DE3752131D1 (de) Impfstoffe und diagnosetest für haemophilus influenzae
DE60028248T2 (de) Verfahren zur Reduzierung der Immunogenität von Staphylokinase durch Entfernen von T-Zell-Epitopen
DE4423392A1 (de) Verfahren zur Identifizierung antigener Peptide
NO933272D0 (no) Reseptor for human follikel stimulerende hormon
ATE233321T1 (de) Verbesserungen in der herstellung von proteinen in wirtszellen
DE68913212T2 (de) Ein reines faktor i-protein und verfahren zur herstellung.
Belluardo et al. Effect of cerebral hemisphere decortication on the cytotoxic activity of natural killer and natural cytotoxic lymphocytes in the mouse
AU5110390A (en) Cdna coding for placental protein 9 (pp9), the isolation and use thereof
MX9709294A (es) Factor de crecimiento de tejido conectivo.
GR900100691A (el) Νευροτροφικός παράγοντας ακτινωτού.